Novel drug targets for the pharmacotherapy of benign prostatic hyperplasia (BPH).
about
Age-related changes in the innervation of the prostate gland: implications for prostate cancer initiation and progressionAlpha-Blocker Treatment Response in Men With Lower Urinary Tract Symptoms Based on Sympathetic Activity: Prospective, Multicenter, Open-Labeled, Observational StudyActivation of innate anti-viral immune response genes in symptomatic benign prostatic hyperplasiaShrinkage of experimental benign prostatic hyperplasia and reduction of prostatic cell volume by a gastrin-releasing peptide antagonistWhat makes the α(1A)-adrenoceptor gene express the α(1L)-adrenoceptor functional phenotype?Hormonal manipulation of lower urinary tract symptoms secondary to benign prostatic obstruction.Crystal structures, absolute configurations and molecular docking studies of naftopidil enantiomers as α1D-adrenoceptor antagonists.The treatment effects of flaxseed-derived secoisolariciresinol diglycoside and its metabolite enterolactone on benign prostatic hyperplasia involve the G protein-coupled estrogen receptor 1.Effect of Selective Prostaglandin E2 EP2 Receptor Agonist CP-533,536 on Voiding Efficiency in Rats with Midodrine-Induced Functional Urethral Obstruction.Resource utilization and costs associated with the addition of an antimuscarinic in patients treated with an alpha-blocker for the treatment of urinary symptoms linked to benign prostatic hyperplasia.Honokiol, a constituent of Magnolia species, inhibits adrenergic contraction of human prostate strips and induces stromal cell death.Contractile signaling pathways in mouse prostate smooth muscle.Smooth muscle contraction and growth of stromal cells in the human prostate are both inhibited by the Src family kinase inhibitors, AZM475271 and PP2.Effect of tamsulosin on the pharmacokinetics of dutasteride in Chinese male healthy volunteers.Factors influencing biased agonism in recombinant cells expressing the human α1A -adrenoceptor.Changes in autonomic nervous system activity after treatment with alpha-blocker in men with lower urinary tract symptoms.Autoantibodies Directed Against the Endothelin A Receptor in Patients With Benign Prostatic Hyperplasia.Inhibition of smooth muscle contraction and ARF6 activity by the inhibitor for cytohesin GEFs, secinH3, in the human prostate.Inhibition of human prostate smooth muscle contraction by the LIM kinase inhibitors, SR7826 and LIMKi3.Combination treatment with naftopidil increases the efficacy of radiotherapy in PC-3 human prostate cancer cells.Development of a P2X1-purinoceptor mediated contractile response in the aged mouse prostate gland through slowing down of ATP breakdown.Implication of Rho-kinase and soluble guanylyl cyclase enzymes in prostate smooth muscle dysfunction in middle-aged rats.Inhibition of Prostate Smooth Muscle Contraction by Inhibitors of Polo-Like Kinases.
P2860
Q27027373-4DE68188-825C-4F32-8A50-5767A59C0813Q35813278-753E5DCC-04CB-4960-BDEE-66F476690873Q36331201-33DEC279-F6E6-4875-A48D-4BF1914ED046Q36617058-1DAA1A1B-75B1-4BBA-B349-CB522D8F5677Q37931304-0B4AD59A-FF38-44F2-939E-796F03F161FAQ38205422-6F1B0179-755D-4908-975C-90433D66C665Q38656213-AC2D9841-888F-4FC7-B142-DB6251DED64CQ38730874-9E3D2715-0B50-46EC-9DA2-84811CA5D767Q39173562-029A924A-683D-4A44-9D54-F573AF08A04EQ41154385-713AFE25-7A21-4FEC-BB5F-A6CF653B25C7Q42931483-315E1D3B-91B9-4B90-9770-5F7E5D5C707CQ44725305-5577F1E0-7DEC-4EFF-88A2-294780C7983BQ47098074-DD00CE3F-4E2E-4D83-90C6-E9CBB6262ADAQ48032152-DB4D0FE6-8FA9-46C2-A1E0-02FFAD0E128FQ48231260-0BAB01B6-894C-4A33-855D-81A7B1B03EC6Q48246036-62DB518E-403C-48B6-9AAF-630FA43D257AQ48924237-18372DC9-AC3E-4172-9576-10CD42765D9FQ50267774-01D3BEE0-E740-4604-B3A4-D209B5E14AA4Q52634022-9E46CABE-2577-4064-9DD8-3B812D7CB39AQ53749396-A97BB262-ED8A-4EED-8E28-327658B5C7EAQ54575593-A7E36756-A844-4C25-BAAC-3C3C2BF3531FQ55026414-92A39B1A-546A-491E-A271-2F0996CC7605Q55361601-D672C41B-ABC9-4A91-AA17-A17A8646F95B
P2860
Novel drug targets for the pharmacotherapy of benign prostatic hyperplasia (BPH).
description
2011 nî lūn-bûn
@nan
2011 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Novel drug targets for the pharmacotherapy of benign prostatic hyperplasia (BPH).
@ast
Novel drug targets for the pharmacotherapy of benign prostatic hyperplasia (BPH).
@en
type
label
Novel drug targets for the pharmacotherapy of benign prostatic hyperplasia (BPH).
@ast
Novel drug targets for the pharmacotherapy of benign prostatic hyperplasia (BPH).
@en
prefLabel
Novel drug targets for the pharmacotherapy of benign prostatic hyperplasia (BPH).
@ast
Novel drug targets for the pharmacotherapy of benign prostatic hyperplasia (BPH).
@en
P2093
P2860
P50
P1476
Novel drug targets for the pharmacotherapy of benign prostatic hyperplasia (BPH)
@en
P2093
P2860
P304
P356
10.1111/J.1476-5381.2011.01332.X
P407
P577
2011-07-01T00:00:00Z